Cells First Biotechnology

Cells First Biotechnology (Beijing) Co., Ltd. is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of advanced cell therapies and providing contract development and manufacturing (CDMO) services. The company's lead therapeutic program, SK-NK (Super Kill-NK), utilizes highly activated allogeneic natural killer cells derived from healthy donors to target advanced malignancies. Currently, SK-NK is being evaluated in Phase 1/2 clinical trials for the treatment of advanced ovarian cancer with massive ascites, administered via intraperitoneal perfusion. Cells First Biotechnology also operates a robust technology platform for cell expansion and activation, supporting both its internal pipeline and external partners in the gene and cell therapy sector.